ARTICLE | Clinical News
Pristiq desvenlafaxine: Phase III data
May 21, 2012 7:00 AM UTC
A double-blind, international Phase III trial in 548 patient responders showed that once-daily 50 mg Pristiq met the primary endpoint of increasing time to relapse, defined as HAM-D17 total score of 1...